Leukotriene E4, 24 Hour Urine

Abbrev Code:TLTE4   
Order Code:LAB8251Order Name:Leukotriene E4, 24 Hour Urine
Methodology:Leukotriene: Liquid chromatography/Tandem mass spectrometry (LC/MS/MS)
Creatinine: Enzymatic colorimetric assay
CPT Codes: 82542 x1, 82542 x1
Test Includes:Leukotriene, Urine; Creatinine, Urine
Turnaround Time:Specimens are sent to the reference laboratory Mon-Fri; tests are performed Mon and Thurs. Results are reported within 2-6 days.

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Collection Instructions

Specimen:24 hour urine collection is the preferred specimen; a random specimen is accepted (order LAB6543).
Optimal Volume:Submit entire collection; analysis requires 5 mL.
Minimum\Peds Volume:5 mL
Container:3 L plastic jug
Collection Instructions:Collect 24 hour urine without preservatives. Store specimen refrigerated during collection.

Processing and Shipping

Specimen Processing:Aliquot 5 mL. Store frozen.
Shipping Instructions:Ship frozen.
Stability:24 hour at room temperature; 7 days refrigerated; 28 days frozen (preferred).
Test Performed at or Referral Lab Lab Sendouts  (Mayo Medical Laboratories)
Referral Lab number:TLTE4


Reference Range:Leukotriene E4: ≤104 pg/mg creatinine  
Creatinine mg/24 h
Males 930-2955
Females 603-1783
  Reference values have not been established for patients who are less than 18 years of age.
Use:An aid to evaluate patients suspected of having systemic mastocytosis using 24 hour urine collections. Systemic mastocytosis (SM) is a heterogenous disorder, including N-methylhistamine (NMH) and 11 beta-prostaglandin F2 alpha (23BPG) analysis along with this test provides a clinical sensitivity greater than 90% and specificity greater than 60%.

Elevated urinary leukotriene E4 (LTE4) concentrations >104 pg/mg creatinine are consistent with the diagnosis of systemic mast cell disease when combined with clinical signs and symptoms. Pharmacological treatment with 5-lipoxygenase inhibitors or leukotriene receptor antagonists has been shown to decrease production of LTE4.

Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
[email protected] for TestID: 6973"